FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Print or Ty	pe Response	s)															
1. Name and Address of Reporting Person* Sigal Charles Elliott					2. Issuer Name and Ticker or Trading Symbol Adaptimmune Therapeutics PLC [ADAP]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_ Director10% Owner					
(Last) (First) (Middle) 32 BREARLY ROAD					3. Date of Earliest Transaction (Month/Day/Year) 05/16/2016							Office	r (give title belo	ow)	Other	(specify below	N)
PRINCE'	TON, NJ ((Street)		4. If Ame	ndmen	t, Date O	riginal	Filed(Mont	th/Day/Y	Year)		Form fil	ual or Joint/0 ed by One Repo ed by More than	orting Pers	on		Line)
(City)		(State)	(Zip)		1	Table I - 1	Non-I	Derivative	Secur	ities Ac	cquirec	l, Dispo	osed of, or I	Benefici	ally Own	ed	
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)		Code		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)			Form: Direct (I or Indire (I)	ct (Instr.	t cial ship		
						Code	V	Amount		Price					(Instr. 4)		
Ordinary Shares with a nominal value of GBP0.001 per share (1)		05/16/2016			P		15,000	A	\$ 1.5 (3)	269,	269,100 ⁽⁴⁾		I	by Sig Famil	-		
Ordinary Shares with a nominal value of GBP0.001 per share (1)		05/17/2016			P		15,000	A	\$ 1.53 (5)	284,	284,100 (6)		I	by Sig Famil			
Ordinary Shares with a nominal value of GBP0.001 per share (1)		05/18/2016	5/18/2016		P		15,000	00 A \$ 1.55 299,100 (8)			I	by Sig Famil					
Ordinary Shares with a nominal value of GBP0.001 per share										52,9	38 <mark>(9)</mark>			D			
Reminder: 1	Report on a s	separate line	for each class of sec	urities benefi	cially o	owned di	rectly	or indirect	ly.								
							cc	ntained i	in this	s form	are no	ot requ	ction of inf uired to res OMB cont	spond	unless	SEC 14	74 (9-02)
			Table II	- Derivative			,		,			Owned					
1. Title of Derivative Security (Instr. 3)	2. 3. Transacti Conversion or Exercise Price of Derivative Security		Execution D any	d 4. Tran Code	<u> </u>		r ai	and Expiration Date (Month/Day/Year)			. Title and Amount of Underlying eccurities Instr. 3 and		Derivative Security (Instr. 5)		tive (cies 1 cially 1 cing 1 ced (ction(s))	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownershij (Instr. 4)
				Coo	le V	(A) (ate xercisable		ration	Title of	lumber					

D 4 0 N /	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Sigal Charles Elliott 32 BREARLY ROAD PRINCETON, NJ 08540	X						

Signatures

/s/ Charles Elliott Sigal	05/18/2016
**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- Dr. Sigal is a manager of Sigal Family Investments, LLC. Dr. Sigal may be deemed to have voting and investment power over the shares held by Sigal Family Investments, LLC. Dr. Sigal disclaims beneficial ownership of such shares except to the extent of any pecuniary interest therein.
- (2) The 15,000 Ordinary Shares are represented by 2,500 American Depositary Shares ("ADSs") which are held by Sigal Family Investments, LLC. Each ADS represents six Ordinary Shares of Adaptimmune Therapeutics plc.
- (3) The price of \$1.50 per Ordinary Share was derived from the purchase price paid on May 16, 2016, of \$8.98 per ADS, divided by six.
- (4) The 269,100 Ordinary Shares comprise (i) 254,100 Ordinary Shares, and (ii) 15,000 Ordinary Shares represented by 2,500 ADSs.
- (5) The price of \$1.53 per Ordinary Share was derived from the purchase price paid on May 17, 2016, of \$9.18 per ADS, divided by six.
- (6) The 284,100 Ordinary Shares comprise (i) 254,100 Ordinary Shares, and (ii) 30,000 Ordinary Shares represented by 5,000 ADSs.
- (7) The price of \$1.55 per Ordinary Share was derived from the purchase price paid on May 18, 2016, of \$9.30 per ADS, divided by six.
- (8) The 299,100 Ordinary Shares comprise (i) 254,100 Ordinary Shares, and (ii) 45,000 Ordinary Shares represented by 7,500 ADSs.
- (9) The 52,938 Ordinary Shares are represented by 8,823 ADSs.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.